Bristol-Myers Squibb (BMY) is making significant moves in recent times, with both the positive and negative implications surfacing for investors. The company's recent slump in stock prices has encouraged an evaluation of BMY's real worth. The acquisition of
Orbital Therapeutics, a $1.5B deal, adds to BMY's commitment towards cellular therapies expansion. Against odds, BMY's Alzheimer's drug,
BMS-986446, has been granted a
Fast Track Status by the FDA. However, the implications of this major deal sent the stocks slipping slightly. On the brighter side, multiple investors like 3Chopt Investments Partners, Aberdeen Group and Mengis Capital Management have elevated their holdings in BMY.
Analysts have however been giving mixed opinions while some propose
Bristol Myers Squibb's stock as a top value stock for long-term investment; others rate it hold due to recent hiccups.
AI collaboration and efforts towards affordable dividend stocks have been appreciated as innovative steps by the firm. Going forward shareholders will be keenly eyeing the
Q3 2025 results and effectiveness of recent acquisitions and FDA approvals.
Bristol-Myers Squibb BMY News Analytics from Fri, 11 Jul 2025 07:00:00 GMT to Sat, 11 Oct 2025 19:15:44 GMT -
Rating 4
- Innovation 6
- Information 8
- Rumor -3
